This #ClinicalTrialsDay, team members Weill Cornell Medicine NewYork-Presbyterian highlight how we’re making a difference through #ClinicalTrials. So proud of the #ClinicalResearch and behind-the-scenes teamwork moving the field forward. Thanks to all the volunteers who participate in #research!

Paul Chapman, MD will be reviewing three abstracts as part of a #Melanoma/#SkinCancer oral abstract session this afternoon at #ASCO24: bit.ly/3yPiKw7

#ASCO24 kicks off today! We’re excited to join our colleagues from across Weill Cornell Medicine at this year’s ASCO meeting.

TODAY: Our Weill Cornell Medicine Meyer Cancer Center director Dr. Jedd Wolchok is chairing and presenting during an #ASCO24 education session on the future of #Melanoma treatment later today. More details: bit.ly/454RTbE

#cutaneousoncology minus Jedd Wolchok Weill Cornell Medicine Meyer Cancer Center #ASCO2024 #gicancersuseimmunotherapytoo WCM Cutaneous Oncology

Our Weill Cornell Medicine Meyer Cancer Center director Dr. Jedd Wolchok (Jedd Wolchok) reflected on study data presented at #ASCO24 that suggested sandwich therapy may not be necessary in #Melanoma patients who respond to neoadjuvant therapy: bit.ly/4c9j6MB

Our ASCO #CancerCast tradition continues! Dr. Manish Shah (Manish A. Shah) joined me for our annual episode where we delve into the most exciting #ASCO24 #research. From #AI to #immunotherapy & #BiTes, we break down what patients and loved ones should know bit.ly/3WNlPql

It was great to have Weill Cornell Medicine Meyer Cancer Center Director and #Immunotherapy expert Dr. Jedd Wolchok (Jedd Wolchok) on Weill Cornell Medicine #CancerCast for a look at the ins and outs of immunotherapy for #cancer, including how it works in the body and common side effects: bit.ly/4fdE7Y0

Dr. Jedd Wolchok (Jedd Wolchok) provided insights regarding the past decade of #Immunotherapy use and development for the treatment of a variety of #cancers and the impact on patient outcomes: bit.ly/4fbH6jJ

#Research led by Dr. Jedd Wolchok (Jedd Wolchok) on the combination of nivolumab and ipilimumab for metastatic #Melanoma may extend patient survival for six years or more compared to the previous average of 6.5 months: yhoo.it/3UIE2UD (cc: Yahoo News)

ICYMI: A combination of #immunotherapy showed #cancer-free survival for 10 years in nearly half of patients with metastatic #Melanoma per Weill Cornell Medicine led research by Dr. Jedd Wolchok (Jedd Wolchok) bit.ly/3YCTnaj

This year’s World Cancer Day theme is "United by Unique." Our collaborative approach to cancer care ensures patients receive top evaluations and therapies, including advancements in precision medicine and immune-based treatments. We make the fight against cancer personal.

Clinical research Weill Cornell Medicine NewYork-Presbyterian is dedicated to innovating, inspiring and transforming lives. On #ClinicalTrialsDay, some of our team members who support clinical research are sharing how we are Powered By Purpose. #CTD2025 ACRP - Assoc. of Clinical Research Profession

Dr. Anna Pavlick breaks down #ClinicalTrial results evaluating RP1 plus nivolumab for certain #Melanoma #SkinCancer patients with OncLive.com: bit.ly/4kBtsZV

WATCH: Dr. Anna Pavlick shares details about a phase 2 #ClinicalTrial for #Melanoma patients who progressed on prior PD-1-directed therapy bit.ly/43ytf2S (cc: OncLive.com)

New York ➡️ Chicago! Excited to see some of our Weill Cornell Medicine @NYPHospital team members at #ASCO25, ready to connect and share insights! Weill Cornell Medicine Meyer Cancer Center WCMHemOncFellow WCM Lung Cancer WCM GI Cancer WCM GU Cancer Weill Cornell Breast Center WCM Cutaneous Oncology

A phase 2 #ClinicalTrial evaluating an injectable medication in combination with pembrolizumab for #Melanoma was presented at #ASCO25. Dr. Jedd Wolchok explains the study results and future next steps: bit.ly/3ZF0mRi

Honored to host CancerCast for Weill Cornell Medicine There is so much to learn and so much to talk about! Available on Apple Podcast, Spotify, or wherever you listen to podcasts! bit.ly/45BV0u0

Sneak peek: From buzzwords to breakthroughs, Dr. Sarah Rutherford (@DrSarahRuth) & I discuss impactful #cancer research in our ASCO #CancerCast #Podcast. Get the latest on targeted therapies, circulating tumor DNA/#MRD testing, minimizing toxicity & more. bit.ly/45ylxaV

Dr. Barbara Ma spoke with @TargetedOncology about the cellular therapy tumor-infiltrating lymphocyte (TIL) therapy for metastatic #Melanoma and the importance of a timely referral: bit.ly/4of5iqC